Dianthus Therapeutics DNTH Second Development Program — Potential Milestone Payments Due
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept dnth:PotentialMilestonePaymentsDue.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's second development program — potential milestone payments due.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Dianthus Therapeutics's second development program — potential milestone payments due?
- Dianthus Therapeutics (DNTH) reported second development program — potential milestone payments due of $3.3M in Q1 2026.
- How has Dianthus Therapeutics's second development program — potential milestone payments due changed year-over-year?
- Dianthus Therapeutics's second development program — potential milestone payments due increased by 3.1% year-over-year, from $3.2M to $3.3M.
- What does second development program — potential milestone payments due mean?
- This metric represents the total future financial obligations triggered by the achievement of specific clinical, regulatory, or commercial milestones associated with a secondary drug development program. It reflects the contingent liabilities inherent in licensing or collaboration agreements that must be settled as the asset progresses through the development lifecycle. Monitoring these obligations is essential for assessing the capital requirements and cash runway necessary to advance the company's pipeline toward potential commercialization.